Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT
October 18 2022 - 4:30PM
Business Wire
Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company
and innovator in seed brachytherapy, and Viewpoint Molecular
Targeting, Inc., a radiopharmaceutical company developing precision
lead-212-based α-particle oncology therapeutics and complementary
diagnostic imaging agents, today announced they will hold an
investor webcast Wednesday, October 19, 2022, at 4:15 p.m. EDT. The
presentation will provide an overview of Viewpoint’s pipeline along
with a review of data presented at this year’s European Association
of Nuclear Medicine conference which concludes on October 19 in
Barcelona, Spain. Speakers on the call will include Isoray CEO Lori
Woods, Viewpoint Molecular Targeting CEO Thijs Spoor, Viewpoint
Molecular Targeting CSO and co-founder Michael K. Schultz PhD,
Geoffrey Johnson MD, PhD, lead investigator on TIMAR1, Vikas Prasad
MD, director of clinical theranostics at the Mallinckrodt Institute
of Radiology at Washington University in St. Louis.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221017005973/en/
The presentation can be accessed at
https://www.webcaster4.com/Webcast/Page/2199/46875.
About Isoray Isoray, Inc. is a medical technology company
pioneering advanced treatment applications and devices to deliver
targeted internal radiation treatments for cancers throughout the
body. Isoray, Inc., through its subsidiary, Isoray Medical, Inc.,
is the sole producer of Cesium-131 brachytherapy seeds. Learn more
about this innovative Richland, Washington company and explore the
many benefits and uses of Cesium-131 by visiting www.isoray.com.
Follow us on LinkedIn and Twitter.
About Viewpoint Molecular Targeting Viewpoint Molecular
Targeting is a radiopharmaceutical company developing precision
oncology therapeutics and complementary diagnostic imaging agents.
The company’s proprietary technology utilizes the isotope lead-212
to deliver powerful alpha radiation specifically to cancer cells
via specialized targeting peptides. Viewpoint is also developing
complementary imaging diagnostics that incorporate the same
targeting peptides which provide the opportunity to personalize
treatment and optimize patient outcomes. This “theranostic”
approach enables the ability to see the specific tumor and then
treat it to potentially improve efficacy and minimize toxicity
associated with many other types of cancer treatments. The
company’s melanoma (VMT01) and neuroendocrine tumor
(VMT-α-NET) programs are entering Phase 1/2a imaging
and therapy trials for the treatment of metastatic melanoma and
neuroendocrine tumors at several leading academic institutions. The
company has also developed a proprietary lead-212 generator to
secure isotope supply for clinical trial and commercial operations.
For more information, please visit the company’s website
www.viewpointmt.com.
About the Merger Viewpoint previously announced on
September 29, 2022 that it has entered into a definitive agreement
to merge with Isoray, Inc. (NYSE AMERICAN:ISR) (“Isoray”), a
medical technology company and innovator in seed brachytherapy.
Additional details regarding the contemplated merger along with the
merger agreement can be found in Isoray’s current report on Form
8-K which was filed with the Securities and Exchange Commission on
September 28, 2022. The consummation of the merger is subject to
approval by the shareholders of both Isoray (who must approve
certain proposals to effectuate the merger but not the merger
itself) and Viewpoint along with other customary closing
conditions.
Forward-Looking Statements – Viewpoint Molecular Targeting
Inc. This press release contains information that includes or
is based upon “forward-looking statements” within the meaning of
the Securities Litigation Reform Act of 1995. Forward-looking
statements provide the company’s expectations or forecasts
regarding future events. These statements can be identified by the
fact they do not relate strictly to historical or current facts.
They may use words such as “believe,” “potential,” “estimate,”
“expect,” “will,” and other terms of similar meaning in connection
with a discussion of future operating or financial performance. In
particular, forward-looking statements include statements relating
to intended future actions; the company’s expectations about its
addressable markets and market share; the consummation of the
merger with Isoray and the realization of the anticipated benefits
of the combination; the functionality and capabilities of the
Company’s therapies; the potential size of the commercial market
for the company’s treatment programs; and the company’s
expectations beliefs, intentions or strategies regarding the
future. Any or all of the company’s forward-looking statements here
and elsewhere may turn out to be wrong. They can be affected by
inaccurate assumptions or by known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements and from
expected or historical results. Many such factors will be important
in determining the company’s actual future results. Consequently,
no forward-looking statement can be guaranteed. The company
undertakes no obligation to correct or update any forward-looking
statements, whether as a result of new information, future
developments, or otherwise, except to the extent required by
applicable law. These forward-looking statements (except as may be
otherwise noted) speak only as of the date of this press release.
Factors or events that could cause the company’s actual results to
differ may emerge from time to time, and it is not possible for the
company to predict all of them.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221017005973/en/
Investor Relations: Mark Levin (501) 255-1910 Media and Public
Relations: Sharon Schultz (302) 539-3747
IsoRay (AMEX:ISR)
Historical Stock Chart
From Jun 2024 to Jul 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From Jul 2023 to Jul 2024